Cost-benefit and cost-effectiveness analysis ofhome artificial nutrition: reappraisal of available data

Influence of age and type of underlying disease on complications related to home enteral nutrition: a single Italian center experience

BACKGROUND

No data about the influence of age and underlying diseases on home enteral nutrition (HEN)-related complications are reported in the literature. Herein, we retrospectively investigated this issue by analyzing HEN-related complications in a cohort of consecutive patients grouped according to the underlying disease and age.

MATERIAL AND METHODS

We reviewed the medical records of 101 patients referring to our team in 2007-2010 to obtain patients' demographic data, age, nutrition status, duration of HEN treatment, and type of HEN-related complications. They were divided in cancer and neurologic patients and subgrouped on the basis of their age. HEN-related complications were expressed as complication rates.

RESULTS

Patients with neurological diseases suffered a significantly higher number of complications as compared with cancer patients (P = .04). Age did not significantly influence complication rates. The mechanical complications were the most frequent. The majority of HEN-related complications were resolved at home.

CONCLUSION

Our data strongly suggest that HEN-related complications are influenced by underlying diseases and not by age. In neurologic patients, dementia, loss of autonomy, and the different therapies administered by PEG probably play an important role in increasing the number of HEN-related complications as compared with cancer patients. The most frequent complications can be managed at home, reducing the costs of hospitalizations and discomfort for the patient.

Home artificial nutrition: an update seven years after the regional regulation

BACKGROUND & AIMS

Home Artificial Nutrition (HAN) is a well established extra-hospital therapy, contributing to decreased health care costs, by reducing the number and length of hospitalizations. The knowledge of the epidemiology of HAN helps plan health-care funding and in analyze the factors that can improve HAN service.

SUBJECTS AND METHODS

An update on the prevalence of Home Artificial Nutrition (HAN) in the Campania region (Southern Italy) and patients clinical characteristics has been regularly carried out in the past seven years after a specific regional regulation issued in 2005.

RESULTS

Total number of patients on HAN has increased from 355 in April 2005 to 1165 in April 2012 (+228.2%); in particular, patients on Home Parenteral Nutrition (HPN) increased from 156 in April 2005 to 306 in April 2012 (+96.2%) and patients on Home Enteral Nutrition (HEN) from 199 to 838 (+321.1%) respectively. HEN/HPN ratio in adults has changed from 1.3/1 in April 2005 to 2.7/1 in April 2012, gradually nearing the expected national mean ratio of 5/1 as observed in the 2005 national survey.

CONCLUSIONS

The specific regional regulation in Campania has contributed to increase the prescription of HAN and to ameliorate its indications; in particular, through the years, HEN is gradually nearing national standards.

Home artificial nutrition in advanced cancer

Attitudes to home artificial nutrition (HAN) in cancer vary greatly from country to country. A 6-year prospective survey of the practice of HAN in advanced cancer patients applied by a hospital-at-home programme in an Italian health district was performed to estimate the utilization rate, to evaluate efficacy in preventing death from cachexia, maintaining patients at home without burdens and distress and improving patients' performance status, and to obtain information about costs. Patients were eligible for HAN when all the following were present: hypophagia; life expectancy 6 weeks or more, suitable patient and family circumstances; and verbal informed consent. From July 1990 to June 1996, 587 patients were evaluated; 164 were selected for HAN (135 enteral and 29 parenteral) and were followed until 31 December 1996. The incidence of HAN per million inhabitants was 18.4 in the first year of activity and 33.2-36.9 in subsequent years, being 4-10 times greater than rates reported by the Italian HAN registers. On 31 December 1996, 158 patients had died because of the disease and 6 were on treatment. Mean survival was 17.2 weeks for those on enteral nutrition and 12.2 weeks for those on parenteral nutrition. Prediction of survival was 72% accurate. 95 patients had undergone 155 readmissions to hospital, where they spent 15-23% of their survival time. Burdens due to HAN were well accepted by 124 patients, an annoyance or scarcely tolerable in the remainder. The frequency of major complications of parenteral nutrition was 0.67 per year for catheter sepsis and 0.16 per year for deep vein thrombosis. Karnofsky performance score increased in only 13 patients and body weight increased in 43. The fixed direct costs per patient-day (in European Currency Units) were 14.2 for the nutrition team, 18.2 for enteral nutrition and 61 for parenteral nutrition. The results indicate that definite entry criteria and local surveys are required for the correct use of HAN in advanced cancer patients, that HAN can be applied without causing additional burdens and distress, and that its costs are not higher than hospital costs.